Palforzia | pharmaphorum

Skip to main content

Saturday 17 May 2025

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

Palforzia

News

peanut allergy

Nestle sells underperforming peanut allergy drug

Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off t

News

After FDA snub, DBV charts a new course for Viaskin peanut

After FDA snub, DBV charts a new course for Viaskin peanut

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was

News

peanuts

NICE backs Aimmune's peanut allergy drug Palforzia for child...

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune's oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS Engla

News

peanuts

DBV craters on FDA’s peanut allergy immunotherapy rejection

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end.

News

Halves of roasted peanuts in bowl and near on dark wooden background, top view

FDA approves first ever peanut allergy therapy from Aimmune

The FDA has approved the first ever peanut allergy treatment, backing Aimmune's Palforzia to reduce reactions in children.

Editor's Picks

Gilead ups its US investment plans by $11 billion

UK trumpets a trade deal with India - but pharma isn't happy

Vinay Prasad will replace Marks as CBER director

Trump's budget would be "catastrophic" for federal R&D

Pharma still in waiting mode after UK-US trade agreement

R&D

Jonah Comstock interviews Dr Dhaval Shah at AAPS

Modelling biologics: Challenges and opportunities, with Dr D...

From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Market Access

Bridging research and clinical guidelines

Sponsored

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company